Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Indeed, patients with clinical benefit exhibited higher levels of these signatures compared to those with lack of benefit; some were statistically significant while others were close to significance (TEFF score, MWW, P = 0.046) (Fig. 2A , Fig.

also in 2,130 other papers